[The fundamental and clinical studies on clindamycin-2-phosphate in the otorhinolaryngologic field (author's transl)].
Fundamental and clinical investigation with a new antibiotic, clindamycin-2-phosphate, were performed with the results which may lead to following conclusions. 1) Concentration in blood: The blood level of clindamycin-2-phosphate in healthy adults who were given 300 mg by intramuscular injection reached a peak level of 4.3 mug/ml one hour after injection. Even after 6 hours, clinically effective serum concentration of 0.5 mug/ml was still demonstrable. 2) Concentration in tissues: Clindamycin-2-phosphate activity was demonstrable at the concentrations of 1.6 approximately 2.3 mug/g in human palatine and mucous membrane of maxillary specimen one hour after the intramuscular injection of 300 mg. Further the concentration was 2.9 approximately 5.4 mug/ml. 3) Results of clinical treatment: When clindamycin-2-phosphate was injected intramuscularly in 30 cases of representative infections in the otorhinolaryngolgic field, it was excellent in 12 cases, good in 12 cases, fair in 4 cases and poor in 2 cases. Excellent and good results were obtained in 24 cases, being the effectiveness 80 per cent. 4) Side effect: No side effect was shown with the intramuscular injection of clindamycin-2-phosphate. The comparative examination of hepatic function, electrolyte and auditory acuity before and after injection showed no significant disturbance.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002908:Chronic Disease; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D005667:Furunculosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D009668:Nose Diseases / Q000188:drug therapy; D009943:Organophosphorus Compounds; D010033:Otitis Media / Q000188:drug therapy; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D010309:Parotitis / Q000188:drug therapy; D000039:Peritonsillar Abscess / Q000188:drug therapy; D012852:Sinusitis / Q000378:metabolism; D014069:Tonsillitis / Q000188:drug therapy
D009943:Organophosphorus Compounds; D002981:Clindamycin